Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...

According to Stoke Therapeutics, over 90% of patients with Dravet syndrome suffer from at least one non ... the potential of zorevunersen as the first disease modifying medicine that addresses the ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote ...

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce ...

Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and ...

Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...

Stoke Therapeutics: The First Gene Silencing Therapy For Dravet Syndrome Sep. 07, 2024 4:03 AM ET Stoke Therapeutics, Inc. (STOK) Stock TAK , OVID , TKPHF , STOK 6 Comments 1 Like Avisol Capital ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions ...

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating prote. ... About Dravet Syndrome.

Stoke Therapeutics , Inc. STOK reported ... in children and adolescents aged two to 18 years with Dravet syndrome. STK-001 is Stoke Therapeutics’ novel proprietary antisense oligonucleotide with ...